세계의 페리틴 검사 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Ferritin Testing Market Growth & Trends:

The global ferritin testing market size is expected to reach USD 1.46 billion by 2030, registering a CAGR of 8.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is growing significantly due to the global prevalence of iron deficiency anemia. According to the World Health Organization (WHO), anemia affects over 1.9 billion people, with iron deficiency being a leading cause. This growing burden, particularly among women, children, and the elderly, is driving the demand for ferritin tests to monitor iron levels. For instance, in India, government initiatives like the Anemia Mukt Bharat campaign emphasize the importance of early anemia diagnosis, boosting the adoption of ferritin testing.

Technological innovations in diagnostics are a key driver of the market. Automated laboratory systems and point-of-care (POC) devices are enabling faster and more accurate ferritin measurements. Companies like Roche and Abbott have introduced advanced immunoassay-based systems that provide precise results with minimal sample volume. For instance, Roche's Elecsys ferritin test is widely used in hospitals and diagnostic labs for efficient anemia management, streamlining workflows, and reducing turnaround times.

Rising awareness of the importance of early diagnosis and preventive healthcare fuels the demand for ferritin testing. Educational campaigns and public health initiatives in regions like Europe and North America encourage routine screening for iron deficiency, particularly for at-risk groups such as pregnant women and children. In the U.S., the Centers for Disease Control and Prevention (CDC) recommend regular anemia screenings for infants and women of childbearing age, contributing to the steady market growth. Emerging economies in Asia Pacific, Latin America, and Africa are witnessing rapid market growth due to improved healthcare infrastructure and increased access to diagnostic services. For example, in China, the government's focus on maternal and child health has led to the widespread adoption of ferritin tests in routine prenatal checkups. Similarly, in Brazil, expanding healthcare access through public programs like SUS (Sistema Unico de Saude) has boosted the use of ferritin tests for anemia diagnosis.

Leading companies in the market, such as Abbott, Siemens Healthineers, and bioMerieux, are pivotal in driving growth. These players are investing in research and development to introduce innovative testing solutions. For example, Siemens Healthineers offers advanced ferritin assays compatible with their Atellica Solution platforms, which integrate seamlessly into hospital laboratories. In addition, collaborations between diagnostic companies and governments, such as partnerships for anemia screening programs, are further expanding the market's reach. Some of the key players in the market are BioMrieux, Humankind Ventures Ltd, Aviva Systems Biology Corporation, Abnova Corporation, and Randox Laboratories Ltd. These players are involved in various strategic initiatives, such as product launches and approvals, to cater to a global clientele.

Ferritin Testing Market Report Highlights:

• Based on product, reagent accounted for the largest revenue share of 45.27% in 2024. The market is being propelled by the growing adoption of immunoassay-based diagnostic techniques like ELISA and chemiluminescent immunoassays, which depend on high-quality reagents for precise and sensitive ferritin measurement. For example, the increasing use of monoclonal antibodies in reagent formulations enhances the specificity and reliability of tests. Companies such as Thermo Fisher Scientific and Roche Diagnostics are driving innovation by developing reagents optimized for automated platforms, further accelerating market expansion. Moreover, the recurring demand for reagents ensures steady revenue, particularly in large diagnostic laboratories and hospitals
• Based on application, anemia dominated the market and accounted for the largest share of 41.47% in 2024. Anemia, affecting one-fourth of the global population, is becoming increasingly common among women, expectant mothers, young girls, and children under 5. By 2021, an estimated 1.92 billion people were living with anemia, a rise of 420 million cases over the last 30 years. This surge is attributed to factors like poor nutrition, chronic illnesses, and limited healthcare access, particularly in developing regions. The growing demand for anemia diagnostics and treatments is driving market growth. Furthermore, the expansion of the global testing market, especially in point-of-care and home-testing devices, is expected to boost this growth, offering more accessible solutions for anemia detection and management
• Based on end use, hospitals dominated end use with the largest market share of 56.32% in 2024. The market growth is fueled by factors such as increasing patient volumes, advancements in medical technology, and the rising demand for specialized treatments. In addition, the expansion of healthcare infrastructure, particularly in emerging economies, plays a significant role in driving this growth. Hospitals are progressively adopting advanced diagnostic tools, including rapid testing devices, to enhance patient outcomes and optimize operational efficiency. These developments are creating a robust demand for innovative solutions in the healthcare sector
• North America dominated the global market, primarily due to the increasing prevalence of iron deficiency anemia and related conditions. Greater awareness of the importance of early diagnosis and monitoring of iron levels is fueling this trend. The aging population and the rising incidence of chronic diseases, such as kidney disease and cancer, which impact iron metabolism, are also driving demand for ferritin tests. Furthermore, advancements in diagnostic technologies, including point-of-care testing and lab-based solutions, are improving accessibility and efficiency, contributing to the market's expansion in the region.
• The Asia Pacific region is expected to witness the fastest growth with a CAGR of 9.23% over the forecast period from 2025 to 2030 due to the presence of manufacturers with innovative devices coupled with accelerated diagnostic research capabilities

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Information Procurement
• 1.2. Information or Data Analysis
• 1.3. Market Scope & Segment Definition
• 1.4. Market Model
  • 1.4.1. Market Study, By Company Market Share
  • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
• 3.5. Market Restraint Analysis
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Product Business Analysis

• 4.1. Ferritin Testing Market: Product Movement Analysis
• 4.2. Instrument
  • 4.2.1. Instrument Market, 2018 - 2030 (USD Million)
• 4.3. Reagent
  • 4.3.1. Reagent Market, 2018 - 2030 (USD Million)
• 4.4. Kits
  • 4.4.1. Kits Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Ferritin Testing Market: Application Movement Analysis
• 5.2. Anemia
  • 5.2.1. Anemia Market, 2018 - 2030 (USD Million)
• 5.3. Hemochromatosis
  • 5.3.1. Hemochromatosis Market, 2018 - 2030 (USD Million)
• 5.4. Lead Poisoning
  • 5.4.1. Lead Poisoning Market, 2018 - 2030 (USD Million)
• 5.5. Pregnancy
  • 5.5.1. Pregnancy Market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. Ferritin Testing Market: End Use Movement Analysis
• 6.2. Hospitals
  • 6.2.1. Hospitals Market, 2018 - 2030 (USD Million)
• 6.3. Diagnostic Laboratories
  • 6.3.1. Diagnostic Laboratories Unit Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Ferritin Testing Market Share By Region, 2024 & 2030
• 7.2. North America
  • 7.2.1. North America Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Target Disease Prevalence
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. Regulatory Framework
    • 7.2.2.5. Reimbursement Scenario
    • 7.2.2.6. U.S. Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
    • 7.2.3.6. Canada Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target Disease Prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Reimbursement Scenario
    • 7.2.4.6. Mexico Ferritin Testing Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.2. Germany
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. Reimbursement Scenario
    • 7.3.2.6. Germany Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.3. UK
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
    • 7.3.3.6. UK Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
    • 7.3.4.6. France Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
    • 7.3.5.6. Italy Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
    • 7.3.6.6. Spain Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
    • 7.3.7.6. Denmark Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
    • 7.3.8.6. Sweden Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
    • 7.3.9.6. Norway Ferritin Testing Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Reimbursement Scenario
    • 7.4.2.6. Japan Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
    • 7.4.3.6. China Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
    • 7.4.4.6. India Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
    • 7.4.5.6. South Korea Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. Australia Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
    • 7.4.7.6. Thailand Ferritin Testing Market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Reimbursement Scenario
    • 7.5.2.6. Brazil Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
    • 7.5.3.6. Argentina Ferritin Testing Market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. Reimbursement Scenario
    • 7.6.2.6. South Africa Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
    • 7.6.3.6. Saudi Arabia Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
    • 7.6.4.6. UAE Ferritin Testing Market, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario
    • 7.6.5.6. Kuwait Ferritin Testing Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Eurolyser Diagnostica GmbH
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Collection Site Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Cortez Diagnostics Inc
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Collection Site Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Pointe Scientific, Inc
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Collection Site Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Humankind Ventures Ltd
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Collection Site Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Aviva Systems Biology Corporation
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Collection Site Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. bioMerieux S.A
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Collection Site Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Abnova Corporation
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Collection Site Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Cosmic Scientific Technologies
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Collection Site Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. CTK Biotech, Inc
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Collection Site Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Thermo Fisher Scientific Inc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Collection Site Benchmarking
    • 8.4.10.4. Strategic Initiatives